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REGULATING RESEARCH WITH VULNERABLE
POPULATIONS: LITIGATION GONE AWRY
JOHN M. OLDHAM, M.D.,*
STEPHAN HAIMOWITZ, J.D.,**

SusAN J. DELANO, B.A.HONS.***
I.

INTRODUCTION

Current litigation in New York, T.D. v. New York State Office of
Mental Health (OMH),' challenges OMH regulations governing research with human subjects. The outcome of this litigation will ultimately determine whether research in New York may be conducted
with children and with incapacitated adults, and under what circumstances. The repercussions may prevent numerous studies from going
forward and ultimately put a halt to research that may have provided
participants with access to effective treatment and significantly improved the well-being of other individuals suffering from mental illness and other cognitive impairments.
The New York experience demonstrates the consequences of litigation in which the central issues of a complex matter are inadequately examined. The result in this instance may be the
establishment of research rules which will have significant adverse impacts on individuals with mental illness or other cognitive impairments, their family members, and researchers in this and other fields.
The New York experience stands in stark contrast to the consensus
* Elizabeth K. Dollard Professor of Clinical Psychiatry, Medicine and Law at Columbia University College of Physicians and Surgeons; Director of the New York State Psychiatric Institute; and Chief Medical Officer of the New York State Office of Mental Health. Dr.
Oldham's teaching and administrative responsibilities include ethical safeguards and concerns in human subject research.
** Attorney with the New York State. Office of Mental Health. His interests include
the law's treatment of autonomy with regard to decision making, the impact of litigation
on social services, and the development of disability policy, particularly with regard to
deafness.
*** Clinical Research Coordinator for the Research Foundation for Mental Hygiene, a
non-profit corporation affiliated with the New York State Department of Mental Hygiene.
A former IRB administrator at the State University of New York at Stony Brook, Ms. Delano
oversees IRBs in state operated psychiatric centers and was a primary author of the New
York regulation concerning psychiatric research.
1. 650 N.Y.S.2d 173 (N.Y. App. Div. 1996), appeal dismissed by 680 N.E.2d 617 (N.Y.
1997), leave to appealgranted by 684 N.E.2d 281 (N.Y. 1997), and appealdismissed by 1997 WL
785461 (N.Y. Dec. 22, 1997) (The final decision in this case post-dated the preparation of
this article.).
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building approach adopted by Maryland, 2 both in its process and
likely outcome.
II.

A.

BACKGROUND

Histoiy of Research in Office of Mental Health Facilities

OMH has included research into the causes of severe and persistent mental illness as one component of its mission for more than 100
years. In 1890, legislation was passed in New York State placing all
chronically mentally ill individuals under the protection and care of
the state.3 Several years later, additional legislation was passed creating the nation's first institute dedicated to psychiatric research. The
New York State Psychiatric Institute (NYPI) opened in 1896 and has
been continuously supported by the state until the present time. NYPI
was mandated to conduct research into the causes, prevention, and
treatment of mental illness.4 A second dedicated research facility, the
Nathan Kline Institute for Psychiatric Research, was opened by OMH
in 1952. Research studies are also conducted at many of the clinical
psychiatric hospitals operated by the state. As recognized by the National Institute of Mental Health, "[t] he State of New York includes
some of the most distinguished research institutions in the United
States."5 Research carried out within OMH facilities is under the overall supervision of a Deputy Commissioner for Research. All research
is carried out subject to the approval of, and ongoing review and monitoring of, a federally-approved institutional review board (IRB).6
Among the milestones accomplished by researchers in OMH were the
discovery of the infectious etiology of "general paresis of the insane,"
the first genetic studies of schizophrenia, the first clinical trials of
chlorpromazine (the first antipsychotic medication to become available in the United States), the first lithium clinic in the country (for
treatment of manic depressive illness), and, more recently, the discovery of the genetic defect in Wilson's disease (a disease of copper metabolism that can cause a type of psychosis).
2. SeeJack Schwartz, Office of Md. Att'y Gen., Third Report of the Attorney General's
Research Working Group (August 1997) (the Third Report is reprinted in Appendix B to
this issue of the Journal of Health Care Law & Policy).
3. See Act of April 15, 1890, ch. 126, 1890 N.Y. Laws 303.
4. See LAWRENCE C. KOLB & LEON ROIZIN, THE FiRTr PSYCHIATRIC INSTITUTE 7-8 (1993).
5. Letter from Rex William Cowdry, Acting Director, National Institute of Mental
Health, to Mr. John V. Tauriello, Deputy Commissioner of Mental Health and Counsel,
New York State Office of Mental Health (January 26, 1996).
6. See Protection of Human Subjects, 45 C.F.R. § 46.101 (1997).
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Research Regulations Prior to 1990

In 1975, the New York State Department of Mental Hygiene, of
which what is now OMH is one component agency, issued regulations
for research involving human subjects. 7 These brief regulations pro-

vided the following:
" Research participation could not come into substantial
conflict with the patient's individual service plan or deprive a patient of any right or privilege. 8
" Informed written consent was required to be obtained
from patients. 9 If a patient did not have sufficient capacity, consent could be obtained from the facility director if
the IRB established that the project had overriding therapeutic importance for a condition presented by the patient and that the project could not be carried out
without the participation of such patients.'
* Use of experimental drugs or treatment procedures had
to be approved by the OMH Division of Research. 1
In the late 1980s, under the leadership of the Deputy Commissioner for Research, the adequacy of these research regulations was
reviewed." Particular attention was given to the need to safeguard
the most vulnerable populations participating in research.' At this
time, a number of significant problems were identified.' 4 As an interim measure, while revised regulations were being developed, OMH
issued a policy memorandum 1 5 which addressed some of the most
critical deficiencies by adding the following requirements:
* Researchers were required to obtain an assessment of capacity of all adult patients, both outpatients and inpatients, and document the results in the individual's
medical record.'" For outpatient protocols which involved no more than minimal risk and/or a non-vulnerable subject population, the IRB was authorized to permit
7. See N.Y. COMP. CODES R. & REcs. tit. 14, § 27.10 (1997).
8. See id. § 27.10(a).

9. See iU § 27.10(b).
10. See id.
11. See id. § 27.10(c).
12. See Memorandum from Heinz Lehmann, Deputy Commissioner for Research, New
York State Office of Mental Health and Susan J. Delano, Clinical Research Coordinator,
Research Foundation for Mental Hygiene, Inc. to OMH Facility Directors and IRB
Chairpersons Uuly 31, 1987) (unpublished memorandum, on file with authors).
13. See id.
14. See id.
15. See id,
16. See id.

19981

RESEARCH WrI

VULNERABLE POPULATIONS

157

the research team itself to make the capacity assessment. 1 7 All other outpatient protocols were subject to
the capacity assessment procedures for inpatient protocols."8 These procedures required that the capacity of inpatients be assessed by at least two people, including an
investigator from the research team and a member of the
treatment team who was not affiliated with the research.' 9
Both were required to be licensed health care professionals, and one was required to be a psychiatrist or clinical
psychologist.20
" For patients found capable of consenting, and with the
patient's consent, family members, significant others, and
close friends who had been involved in treatment decisions were to be informed about the patient's decision to
participate. 2 '
* Consent for an incapable patient's participation in research was required to be obtained from both the facility
director and the patient's spouse, parent, adult child,
guardian, or court of competent jurisdiction. 22 Documentation of the patient's lack of objection to participation was required.23
* The researcher was required to honor the incapacitated
patient's objection to participation unless a court order
was obtained.2 4 It was assumed that a court would only
authorize research offering therapy not available outside
the research context where there was no acceptable alternative treatment and the research
was consistent with the
25
treatment needs of the patient.
C. Development of 1990 Regulations
As noted above, the 1975 regulations were inadequate, particularly with regard to issues of capacity and-surrogate consent. 26 Building on the interim guidelines, OMH undertook a revision of its
research regulations. Three major goals guided this process:
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.

See
See
See
See
See
See
See
See
Se

id.
id.
id.
id
id at 2.
id. at 3.
id.
id at 4.
id
See N.Y. COMP.

CODES

R. & REGS. tit. 14 § 27.10 (1997).
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1) maximization of patient autonomy and control by patients over their participation in research;
2) protection of the rights and welfare of these potentially
vulnerable populations; and
3) creation of an environment that makes it possible to
important and needed research with these patient
carry out
27
groups.

In drafting the regulations, OMH attempted to achieve a principled and workable balance of these goals. Based upon clinical reality,
respect for patients and developments in the law, a consensus had developed among health professionals that psychiatric patients should
be presumed capable of consenting to research participation. 28 Moreover, status as an inpatient or outpatient was not to be considered
determinative of capacity.2 9 However, since some patients do lack capacity to consent, IRBs were charged with the responsibility of examining the proposed research and the subject population to tailor
30
capacity assessment procedures to the specific research protocol.
When an IRB had reason to believe that patients might lack sufficient
capacity to give informed consent, the IRB was authorized to require
that capacity assessments be conducted by someone not affiliated with
the research and to set specific qualifications for the person(s) who
31
assessed capacity.
The regulations also provided that a member of the participant's
treatment team was required to approve all research that involved
more than minimal risk.3 2 The care and treatment of hospitalized patients is under the direction of a multi-disciplinary treatment team,
usually consisting of a psychiatrist, social worker, nurse, activities therapist, and often a psychologist.3 3 This treatment arrangement is standard for all inpatients, including those participating in research
protocols.
In addition, the regulations stated that all patients, regardless of
capacity, could, at any time prior to or during participation in re27. See Susan J. Delano & Jay L. Zucker, ProtectingMental Health Research Subjects Without
ProhibitingProgress, 45 HosP. & COMMUNITY PSYCHIATRY 601-03 (1994).
28. See Rivers v. Katz, 495 N.E.2d 337, 342-43 (N.Y. 1986).
29. See N.Y. COMP. CODES R. & REcs. tit. 14 § 527.10.
30. See id. § 527.10(e) (2) (ii).
31. See id.
32. See id. § 527.10(d)(3). "Minimal risk" is defined to mean that "the risks of harm
anticipated in the proposed research are not greater... than those ordinarily encountered
in daily life or during the performance of routine physical or psychological examinations
§ 527.10(d)(5) .
or tests."
33. See Paul Rodenhauser, Psychiatristsas Treatment Team Leaders: Pitfalls and Rewards, 67
PSYCHiATRIC Q. 11 (1996).

19981

RESEARCH WITH VULNERABLE POPULATIONS

search, object and be withdrawn from participation. 34 For incapable
participants, the objection of any of the members of the classes of
authorized surrogates was equally effective.35 Any such objection was
determinative except that, if the research provided a prospect of direct benefit available only in the context of the research, participation
in such research could occur if approved by a court.3 6 Moreover, the
IRB was required to determine, for research involving incapable subjects, that the research could not be done without such subject's inclusion and that the research was likely to produce knowledge of
importance for a condition presented by the
overriding therapeutic
37
patients in question.

Finally, preference was to be given to surrogates chosen by the
patient. 3 In the absence of a patient-chosen surrogate, consent could
be obtained from a patient's spouse, parent, adult child, adult sibling,
or guardian.3 9 If no surrogates in the other categories were available,
consent could be obtained from a court or, in special cases, (e.g., persons in non-traditional relationships) consent could be provided by a
carefully defined "close friend."4 ° This identification of potential
surrogate decision-makers reflected the provisions found in the New
York state statute enacted in 1987 concerning "Do Not Resuscitate"
orders.4 '
Two additional factors regarding the OMH regulations are relevant to this discussion. The first is that the OMH regulations supplemented the federal regulations which govern how human subjects
research is conducted in this country.4" The OMH regulations did
not establish or change any principles or categories with regard to
likelihood of therapeutic benefit of the proposed research, degrees of
risk or funding source.
The second factor was that the process of developing the regulations included extensive consultation with patient advocates, clinicians, researchers, state agency personnel - particularly the
Department of Health and members of IRBs. Thereafter, as required
34.
35.
36.
37.
38.
39.
40.

See§ 527.10(e)(2) (vi), (vii).
See § 527.10(e) (2) (viii).
See § 527.10(e)(2)(vi-viii).
See § 527.10(d) (6).
See § 527.10(e)(2)(iii), (iv).
See § 527.10(e) (2) (iv).
1&

41. N.Y. Pua. HEALTH LAw §§ 2960-72 (McKinney, 1997).
42. See Protection of Human Subjects, 45 C.F.R. § 46 (1997) (now referred to as the
Common Rule); Protection of Human Subjects, 21 C.F.R. § 50 (1997); Institutional Review
Boards, 21 C.F.R. § 56 (1997).
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by state law, 4" draft regulations were published in the State Register
for comment. 4 The proposed regulations were also distributed to
state agencies, facilities licensed and operated by the OMH, local government units, the Mental Health Services Council (an advisory
group, to the OMH Commissioner), consumer groups, and advocacy
groups. A number of groups provided comments. 4 5 These comments
questioned many aspects of the proposed regulations, including their
applicability, definitions, and issues related to surrogate consent. Following are summaries of the comments that are relevant to the issues
46
raised in the litigation:

* Six comments stated that research involving incapable
subjects should only be permitted when it involves a benefit to the subject. OMH responded that while benefit to
an individual patient is highly desirable, research into
many currently irreversible conditions such as Huntington's Disease and Alzheimer's Disease cannot benefit the
subjects of the research.4 7 To prohibit research when
there is no direct benefit to the patient would mean the
end to research into many serious illnesses. To clarify
that the IRB is required to conduct a risk/benefit analysis, the proposed regulations were revised to give greater
emphasis to the sections of the federal regulations relating to evaluation of risks and benefits, and the minimization of risks.4"
" One comment suggested that when a person's capacity is
questionable and the research involves more than minimal risk, an independent qualified consultant should determine capacity. 49 OMH responded that the proposed
regulations required the IRB to evaluate the nature of the
research and the subject population to determine when
43. See N.Y. A.P.A. LAw §§ 201-02 (McKinney, 1997).
44. See Mental Illness Research, N.Y. St. Reg., May 23, 1990, at 23-24 (codified at N.Y.
COMP. CODES R. & REGs. tit. 14, § 527.10 (1997)).
45. Twenty one comments were timely received. These were submitted by mental
health professionals and providers such as state and county Mental Health Associations,
and operators of licensed psychiatric inpatient units; by advocacy groups such as Project
Release, Mental Health Recipient Empowerment Project, and the Commission on Quality
of Care for the Mentally Disabled; and by individuals. In addition, a submission by Disability Advocates, Inc. which was received subsequent to the time period for comments established by the New York State Administrative Procedure Act was also considered.
46. See generally Mental Illness Research, N.Y. St. Reg. August 29, 1990, at 27-31 (1997)
[hereinafter Mental Illness Research].
47. See id. at 30.

48. See id.; see also Protection of Human Subjects, 45 C.F.R. § 46.111 (1997).
49. See Mental Illness Research, supra note 46, at 30.
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an independent assessment of capacity is required."0
This complex decision is best left to the judgment of the
IRB.
Two comments stated that the decision in Rivers v. Katz"l
requires that capacity assessments/determinations must
be made by a court.5 2 This is not OMH's interpretation
of the Rivers opinion."3 Such a requirement would mean
that all patients would be presumed incapable of consenting until a judicial determination of capacity is
made.5 4 This stigmatizing practice would be detrimental
to OMH's ability to provide treatment and would impose
a tremendous and unwarranted barrier to the conduct of
research.5
Two comments stated that it should be conclusively assumed that all patients have sufficient capacity to consent.5 6 OMH disagreed believing that some patients
would lack capacity, and thus, safeguards are required to
ensure that the interests of those patients who lack capacity are protected.5 7 The IRB must determine who shall
assess capacity, and the person obtaining consent must
58
sign the consent form to attest to the person's capacity.
Eleven comments challenged surrogate consent.5 9 OMH
responded that the surrogates named in the regulations,
particularly those chosen by the patient, can more appropriately articulate the patients' wishes and interests than
60
can judges.
Four additional comments challenged the authority of a
"close friend" to consent on behalf of an incapable subject.6" OMH responded that "close friend" was incorporated in recognition of the large number of people in
non-traditional relationships and the large number of
people whose primary care giver is not a family mem-

50. See id.
51. 495 N.E.2d 337 (N.Y. 1986).
52. See Mental Illness Research, supra note 46, at 30.
53. See id.
54. See id.
55. See id.
56. See id.
57. See id.
58. See id.
59. See id. at 30-31.
60. See id. at 31.
61. Id.
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ber.6" As noted above, this principle had already been
recognized in New York law."3
* Nine comments asked for specification of the conditions
under which an application could be made for a court
order to override a patient's objection.6 4 This suggestion
was adopted.
" One comment objected to any provision allowing an incapable subject's objection to be overridden.6 5 OMH responded that the override provision is intended for
situations in which there is no standard treatment for a
condition or the patient is refractory or intolerant of standard therapy.' This would allow treatment over objection with an experimental drug, but only when
specifically authorized by a court.
Based upon the public comment, the proposed regulations were
revised. The revised proposed regulations were distributed, the seven
responses received, again presenting divergent perspectives, and all
responses were considered prior to final adoption.6 7
D. Experience with 1990 Regulations
It appears that researchers and IRBs made the transition from the
minimal 1975 regulations to the 1990 regulations in a workable manner. The regulations were in effect for approximately five years, and
other than the litigation, we are aware of no complaints about the
regulations or their implementation. It should be noted that many
avenues for complaints were available including the Commission on
Quality of Care for the Mentally Disabled, an independent state oversight body. Moreover, as required by the federal research regulations, 68 all research consent forms include the name and telephone
number of a person that participants (or surrogates) may contact if
they have any questions about their rights.6" Typically this person is
the IRB chairperson. In addition, individuals and organizations routinely contact the Commissioner of OMH with questions and concerns, but no complaints regarding the research regulations were
62. See id.
63. N.Y. PuB. HEALTH LAW §§ 2960-72 (McKinney, 1997).
64. See Mental Illness Research, supra note 46, at 30.

65. See id.
66. See id.
67. These comments were submitted by Disability Advocates, Inc., New York Lawyers

for the Public Interest, Inc., the Free Association for Rights and Representation, Inc., two
individuals and two representatives of research institutions.
68. See Protection of Human Subjects, 45 C.F.R. § 46.116(7) (1997).
69. See id.
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received to our knowledge. Finally, the regulations were described in
a widely read peer-reviewed publication, 7" and the Federal Office for
Protection from Research Risks has noted its appreciation of "the
commitment of the New York State Department of Mental Health to
the protection of human subjects."7"
III.

SETTING RESEARCH POLICY. THROUGH LITIGATION

A. Summary of Plaintif[s Claims
While the 1990 regulations were considerably more protective of
research participants than the previous regulations; they were substantially flawed in the opinions of some groups. In 1991, three legal advocacy groups - Disability Advocates, New York Lawyers for the Public
Interest, and The Mental Hygiene Legal Service, on behalf of six patients hospitalized at various New York State Psychiatric Centers
brought the T.D. case against OMH and the State Department of
Health.72 None of the six patients claimed to have been a participant
in a research project. However, they alleged that they were "fearful"
of being included in research against their will. 73 These patients had
received standard medications administered over their objections, 7 in
accordance with a 1986'ruling of New York's highest court permitting
such treatment upon ajudicial determination that the patient-was incapable of making treatment decisions and that the proposed treatment was appropriate.7 5
The TD. suit concerned both OMH operated facilities as well as
OMH licensed facilities (i.e., psychiatric units in general hospitals and
in teaching hospitals affiliated with academic departments of psychiatry) in New York and was limited to more than minimal risk research
with minors and with adults who lack capacity to consent. 76 The plaintiffs asserted a legal claim with two main elements:
70. See generally Delano & Zucker, supra note 27.
71. Letter from J. Thomas Puglisi, Director, Division of Human Subject Protections,
National Institutes of Health, to Susan Delano, Clinical Research Coordinator, Research
Foundation for Mental Hygiene, Inc. (December 2, 1996) (unpublished letter on file with

authors).
72. T.D. v. New York State Office of Mental Health, 626 N.Y.S.2d 1015 (N.Y. Sup. Ct.
1995), affd 650 N.Y.S.2d 173 (App. Div. 1996), appeal dismissed &y680 N.E.2d 617 (N.Y.
1997), leave to appealgranted by 684 N.E.2d 281 (N.Y. 1997), and appeal dismissed by 1997 WL
785461 (N.Y. Dec. 22, 1997).
73. T.D., 650 N.Y.S.2d at 177.
74. See id.
75. See Rivers v. Katz, 495 N.E.2d 337, 343 (1986).
76. T.D., 626 N.Y.S.2d at 1017.
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. 1) that OMH lacked the authority to. promulgate regulations regarding research on human subjects because state law granted such
authority to the Department of Health;" and
2) that the specific regulations governing the procedures for the
"non-consensual participation by mentl: patients in potentially high
risk [non-therapeutic] experiments" s violated constitutional rights to
privacy and due process by permitting, inter alia, research consent
from a relative or "close friend" without a judicial determination of
incapacity and formal designation of a surrogate.7 9
The parties filed cross motions for summary judgment on these
legal claims in 1992.80 Plaintiffs alleged that risk and harm were associated with research participation, but as the motions addressed only
questions of law, these allegations were never proven nor rebutted.'
Moreover, neither the actual risks and benefits of research participation nor the concepts and mandates of the federal regulations and
state law governing the conduct of research was ever meaningfully explored in this litigation.
In 1995, the court granted the Plaintiffs' Motion for Summary
Judgment, stating clearly that it was not ruling on the constitutional
claims but only on the question of OMH's statutory authority to issue
regulations concerning research."2 The court further limited the
scope of its ruling to non-federally funded research studies.8 "
Defendants appealed the trial court's statutory ruling, and the
plaintiffs appealed that court's failure to rule on the constitutional
issues.8 4 In 1996, the intermediate appeals court, the First Appellate
Department of the New York State Supreme Court, issued its decision
on the cross appeals of the trial court's ruling on the cross motions for
summary judgment."5 The appellate court concurred with the lower

77. See id. at 1021.
78. Id. at 1017.
79. See id.
80. See id. at 1018.
81. Plaintiffs motion for summaryjudgment was supported by affidavits which claimed
research participants were exposed to extreme risk and suffered terrible harms. In support
of these claims, plaintiffs attached over 2,500 pages of excerpts from investigative resports,
consent forms, the Physicians Desk Reference, etc. Defendants contended that, when read
in their entirety, the reports, forms and PDR demonstrated the inaccuracy of the conclusions drawn by the plaintiffs.
82. See T.D., 626 N.Y.S.2d at 1022-23.
83. See id. at 1023-24.
84. See T.D., 650 N.Y.S.2d 173.
85. See id.
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court that OMH lacked the statutory authority to issue the regulations,
and also ruled on the constitutional questions. 6
Many aspects of the court's constitutional analysis and conclusions are confusing, but the essence of the ruling was that the OMH
regulations violated the right to due process in that they did not specify uniform qualifications and protocols for the independent evaluation of research participants' mental capacity, did not provide for
notice of that evaluation to the person or a means to object to the
determination, permitted a relative to give surrogate consent without
a judicial proceeding, and thus permitted non-therapeutic research
which posed "more than minimal risk" to research subjects without
their consent or the consent of a suitable surrogate." Like the lower
court, the decision clearly states that it applies only to non-federally
funded and non-therapeutic research."8 The court held that individuals who lack decision-making capacity may not participate in such research if that research poses more than minimum risk to the research
subject unless the research subject has previously given valid "specific
consent" or a suitable surrogate chosen by the subject has given consent.8 9 Although the plaintiffs obtained two court decisions invalidating the regulations, they returned to the appellate division requesting
that it clarify its decision and broaden the scope to apply to federallyfunded studies and to therapeutic studies with the populations in
question.9" OMH also asked the court to clarify its decision, but both
motions were denied. 9 '
Plaintiffs then appealed to New York's Court of Appeals, the
state's highest tribunal, again seeking to broaden the scope of the ruling to apply to federally-funded and to therapeutic research involving
incapable adults and minors.92
B.

ReallocatingAgency Jurisdiction

The plaintiffs have contended, and the courts have thus far
agreed, that the New York State Department of Health (DOH) has
sole legal authority to issue regulations concerning human subject research. 9" It is true that DOH has authority in this area under New
86. See id. at 184-94.
87. Id.
88. See idat 184, 192.
89. Id.at 177.
90. See Plaintiffs'-Appellants' Notice of Motion for Leave to Appeal at 23-35, 650
N.Y.S.2d 173.
91. See T.D., 650 N.Y.S.2d at 176.
92. See id (at the time of the original writing of this article, the appeal was pending).
93. See i&
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York State Public Health Law;9 4 yet the court ignored important facts.
It had been a longstanding understanding between DOH and OMH
that OMH had the authority to issue regulations which provided specific requirements for psychiatric research. In fact, DOH had not
promulgated regulations regarding human subjects research, but had
participated in the development of, and had recognized, the OMH
regulations and system for monitoring psychiatric research. This reliance upon OMH expertise in exercising administrative responsibility
continues, for example, with OMH licensing the psychiatric units in
general hospitals whose overall licensure is statutorily committed to
DOH. Thus the court's invalidation of the OMH regulations upset interagency coordination that had worked well for years, and did so for
reasons having nothing to do with the substance of the research
regulations.
C. Misperception of Risks and Benefits
As noted above, none of the plaintiffs in the law suit had suffered
any tangible harms as a result of participation in research, since, in
fact, none of them had participated in research. Rather, the suit was
based on their fears that they might be included in a research protocol without their informed consent. 95 Because there was no real harm
suffered, the claims were based upon hypothetical harms. Unlike
cases where actual injury is suffered and the lawyers for the plaintiffs
must litigate based upon evidence of harm,. in this case the lawyers
were free to assert possible harms untethered to facts. The structure
of the litigation thus lent itself to rhetoric. Moreover, because the
trial court ruled on motions for summary judgment and no real factual record was developed, the appellate review of the issues reflected
the emotions associated with risk and vulnerability rather than the reality of research.
The plaintiffs contended that high-risk research was being carried
out with minors and incapable adults, and that this high-risk research
9 7 In thenopapers
offered absolutely
benefitfiled
to the
participants"
and
was akinplaintiffs
to Nazi
atrocities.
with
the court of
appeals,

94. See N.Y. PuB. HEALrH LAw § 2446 (McKinney, 1997).
95. See TD. 626 N.Y.S.2d 1015.
96. See Plaintiffs' Complaint at para. 21, 28, T.D. v. New York State Office of Mental
Health, 626 N.Y.S.2d 1015 (N.Y. Sup. Ct. 1995) (No. 5136/91); Plaintiffs'-Appellants' Statement in Support of Motion for Leave to Appeal at 4, T.D. v. New York State Office of
Mental Health and New York Department of Health, 650 N.Y.S.2d 173 (App Div. 1996)
(No. 5136/91) [hereinafter Plaintiffs'-Appellants' Motion for Leave to Appeal].
97. See Patricia Cohen, Patientsat Risk: Experiments in Mental Hospitals, NEw YORK NEwsDAY, Feb. 3, 1993, at 3. "'We may not have the horror stories in numbers, but the possibility
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made the following statement: "This appeal raises. novel issues which
are of paramount importance to patients in psychiatric facilities who
cannot defend themselves from non-consensual experiments which
present a significant risk of harm and death and which may not even
offer an iota of benefit."9 Plaintiffs proceeded to repeatedly refer to
"risky," "wholly non-therapeutic" experiments. 9
The plaintiffs' paper's also stated,
iT]he OMH experiments involve both "FDA approved and
non-FDA-approved experimental antipsychotic and psychotropic drugs" and "highly invasive painful testing procedures" such as spinal taps, inhalation of radioactive gas,
attachment to intravenous lines for several hours, radiation
exposure, and skin biopsies ....The experiments are "capable of causing permanent harmful or even fatal side
effects."'00
Contrary to these assertions, to the best of our knowledge, in facilities operated or licensed by OMH, no studies are done that do not
involve patient assent,' 0 1 no non-therapeutic elements of any studies
involve more than a minor increase over minimal risk, and there are
no more than a minor increase over minimal risk studies that are
"wholly non-therapeutic." The categorization of risk in human subjects research presents a number of complicated issues. However,
utilizing generally accepted definitions, 0 2 no high-risk research is being carried out, to our knowledge, in OMH operated or licensed facilities. In addition, the procedures the plaintiffs refer to are all
performed in the course of ordinary medical care in hospitals all over
the country. They are not highly invasive, they are either not painful
or are only minimally so, and the drug side effects referred to are
those listed in the Physicians'DeskReference as potential side effects of
FDA-approved medications routinely prescribed in standard psychiatric treatment.
of what happened in Nazi prison camps or Tuskegee exists' said Ruth Lowenkron, an attorney with New York Lawyers for the Public Interest who argued the case in State Supreme
Court in Manhattan." Id. at 3.
98. Plaintiffs'-Appellants' Motion for Leave to Appeal, supra note 96, at 20.
99. Id.
100. Id.
101. Though the regulations contemplated the possibility that court authorization for
treatment over objection could be sought to provide necessary treatment not otherwise
available, we are not aware of any case in which such authorization has been sought.
102. See Evan G. De Renzo, Decisionaily Impaired Persons in Research: Refining the Proposed
Refinements, 25J.L. MED. & ETHICS (1997).
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D. Shrinking the Category of TherapeuticResearch
While the litigation was proceeding, numerous attempts were
made to settle the matter through face-to-face dialogue between the
parties. One issue that was particularly contentious was how to characterize research that was expected to benefit participants and contained a non-therapeutic element.
Plaintiffs insisted on rigidly
categorizing every research protocol as either therapeutic or non-therapeutic. They defined any protocol, in its entirety, as non-therapeutic
if any element of the protocol was non-therapeutic, thus significantly
shrinking the category of research considered therapeutic.'
The consequences of this categorization are very significant. For
example, protocols involving non-therapeutic uses of procedures such
as Positron Emission Tomography (PET) scans, no matter how much
potential benefit they otherwise offer, are classified as non-therapeutic
because of such categorization. Although plaintiffs' basis for classifying research was never examined by the courts, the appellate division's decision effectively adopted their classification and banned all
non-therapeutic, more than minimal risk research involving minors or
incapable adults, unless such. research is federally-funded."0 4
In New York, IRBs have traditionally been responsible for evaluating risk/benefit ratios of protocols, to assure that even if a protocol
contains non-therapeutic elements, the overall benefits of the proto0 5
col outweigh the risk of the non-therapeutic elements in question.
Guidance was provided to the IRBs by the OMH regulations, which,
for emphasis, repeated the federal requirements for approval of research."0 6 The OMH regulations also provided that treatment teams
must approve more than minimal risk research 0 7 and stipulated that
incapable adults could only participate in research if it could not be
done without their participation and only if the knowledge likely to be
produced had overriding therapeutic importance for the understand103. At one point in the litigation, before the appellate division decision, the defendants agreed to a stipulation reflecting this categorization in exchange for an amendment of
the definition of "therapeutic." Stipulation of Feb. 9, 1996, 626 N.Y.S.2d 1015 (Sup. CL
1995) (Index No. 5136/91). This definition had included the language "and is only available in the context of research," which would have allowed only research involving investigational drugs and would have banned all research involving marketed drugs thus
adversely impacting research seeking to establish lower dosage levels of medications. 1d.
104. See T.D. v. New York State Office of Mental Health, 650 N.Y.S.2d 173 (App. Div.
1996), appeal dismissed, 680 N.E.2d 617 (N.Y. 1997), leave to appeal grantedby 684 N.E.2d 281
(N.Y. 1997), and appeal dismissed by 1997 WL 785461 (N.Y. Dec. 22, 1997).
105. See N.Y. COMP. CODs R. & REas. tit. 14, § 527.10'(1997).
106. See id. § 527.10(d).
107. See id. § 527.10(d)(3).
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ing or treatment of a condition presented by the patient in
question.?10

Although we disagree with the plaintiffs' categorization of procedures like lumbar punctures or PET scans as "highly risky," it is true
that these procedures might be viewed by some as acceptable if necessary diagnostic or therapeutic components of treatment, but not acceptable as non-therapeutic components of a research protocol, even
if the protocol is otherwise therapeutic. However, the small degree of
risk or discomfort caused by the non-therapeutic procedure is minimal in contrast to the substantial morbidity or mortality of the condition being studied (e.g., schizophrenia, suicidal depression) and the
anticipated benefit to the subject from the therapeutic aspects of the
protocol that may be largely or entirely unavailable outside of the context of research.
Absent specific evidence of adverse consequences from the nontherapeutic use of common diagnostic procedures, absolutely banning their use unnecessarily impedes the development of better treatments, which is particularly unjustified given the overall benefits to
research participants. If problems were to be identified regarding
such use, tailored standards or mechanisms should be explored
before an absolute legal ban is considered.
E. Combining Rigid Categories and Risk Exaggeration
Another fundamental difference between the plaintiffs and OMH
concerned the use of the concept of a "minor increase over minimal
risk."1" 9 Although this level of risk classification was proposed by the
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1 ° and adopted in the federal regulations regarding research involving children,"1 the plaintiffs would
not accept the concept. As a result, research posing only a minor increase over minimal risk was categorized along with highly risky research as simply "more than minimal risk" and thus banned under the
court's ruling.
"Minimal risk" is defined in the federal research regulations to
the effect that "the probability and magnitude of harm or discomfort
anticipated .inthe research are not greater in and of themselves than
108. See id § 527.10(d)(6).
109. THE NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS: RESEARCH INVOLVING
CHILDREN, DHEW Pub. No. (OS) 77-0004 at 8 (1997).

110. See idat 7-9.
111. Protection of Human Subjects, 45 C.F.R. § 46.406(a) (1997).
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those ordinarily encountered in daily life or during the performance
of routine physical or psychological examinations or tests.""' 2 The
provisions in the federal research regulations concerning children
permit research which is not expected to benefit the child and involves risk that is only a "minor increase over minimal risk" if certain
conditions are met." 3 Although this risk level is not further defined
by the regulations, its application to research involving minors includes an instruction to IRBs to evaluate the experiences ordinarily
encountered by the subjects, including their experiences during the
course of regular treatment, in making its determination about the
risk posed by a research intervention to a particular subject
4
population. 1
Examples of elements in OMH protocols determined by IRBs to
be non-therapeutic and more than minimal risk, which plaintiffs repeatedly referred to as "highly risky," are PET scans and lumbar punctures. We would argue that these procedures should be categorized as
no more than a minor increase over minimal risk, an argument others
make as well:
There are those who argue that... [LPS and PET scans]
are, if not minimal risk, not more than a minor increase
above minimal risk. Although LPS and PETs are not on the
list of minimal-risk procedures contained in the U.S. research ethics regulations, Title 45, Code of Federal Regulations, Part 46 (45 C.F.R. 46), this list has not been updated in
many years and these procedures may eventually be
added." 5
In fact, in New York, no more than minimal risk non-therapeutic
research elements are carried out that we know of with the populations in question where the non-therapeutic elements present more
than a minor increase over minimal risk to participants.
In its now invalidated research regulations, 1 6 OMH had attempted to supplement federal regulations and provide overall guidance to IRBs as they carefully weighed the risks and benefits of
research protocols. OMH's goals were to require reasonable protection for patients while acknowledging their autonomy, yet at the same
time to avoid setting barriers so high that they could block scientific
112. !d. § 46.102(i).
113. Id. § 46.406(a).
114. See id. § 46.406(b).
115. Evan G. DeRenzo, Surrogate Decision Makingfor Severely Cognitively Impaired Research
Subjects: The Continuing Debate, 3 CAMBRIDGE Q. HEALrHCARE ETHics 539, 540 (1994).
116. See N.Y. COMp. Coos R. & REGS. tit. 14, § 527.10 (1997).
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progress -progress, to .benefit the very patients being protected. The
plaintiffs' argument that, research with children or..incapable adults
could be continued by simply deleting any non-therapeutic more than
minimal risk elements disregards. the realities of scientific research.
Some vitally important questions can only be addressed by employing
procedures that are not entirely risk-free but provide answers that
could lead to important therapeutic benefits. Risk is encountered
daily in routine health care, in the form of diagnostic evaluations to
"investigate" the etiology of clinical symptoms. For example, procedures such as PET scans, angiograms, laparoscopies, or even "exploratory" laparotomies are carried out to search for the disease source,
with no guarantee that positive findings will result. In our view, small
increments of risk are at times necessary in the context of carefully
conducted clinical research in order to find ways to relieve the extreme pain and suffering of severe mental illness.
IV.

IMPACr OF NEW YORK LITIGATION

Unless corrected by the New York State Court of Appeals, the decision as now written by the New York courts will mean that some significant research that is currently being conducted on mental illness
will not be able to continue, as. illustrated in the following two
examples:
1. A major academic department of psychiatry has a large portfolio of foundation-funded research." 7 Researchers at this institution
recently described their plan to begin a sensitively and carefully
designed PET brain-imaging study of autistic children."' Childhood
autism is a pervasively disabling, severe condition. New findings are
crucial to better understand this condition, and taking advantage of
new non-invasive brain-imaging technologies makes eminent sense.
The researchers had to be informed that because this study was nontherapeutic, it was now illegal in New York.
2. At NYPI, a study is being carried out of suicidal adolescents.
Suicide is the second leading cause of death among adolescents age
15-19, and it has increased by over 300% since 1950 in this age
group." 9 Studies in adults have revealed low central nervous system

117. Personal communication between David Silbersweig, M.D., Cornell Medical College, and John Oldham, M.D., Director, New York Psychiatric Institute (March 26, 1997).
118. See id.
119. See Alan L. Berman & David A. Jobes, Suicide Prevention in Adolescents (Age 12-18), 25
SUICIDE & LIFE THREATENING BEHAVIOR 143 (1995).
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serotonin levels in certain patients at highest risk for suicide. 120 Other
studies, however, have established that one cannot automatically apply
findings that hold in adults to younger populations.' 2' The study in
question involves hospitalizing highly suicidal youngsters at NYPI, and
providing at no cost to them, several months of enormously therapeutic intensive inpatient treatment. 2 2 These minors assented to participate in the research, and their parents gave informed consent.2 2 A
crucial component of this study is the performance of a lumbar puncture, or spinal tap, a diagnostic procedure, of which the main risk is
that, in about ten to fifteen percent of cases, it causes a bad headache,
which usually subsides within twenty-four hours.' 24 It is a test that is
carried out every day in every general hospital. Because this more
than minimal risk procedure is non-therapeutic, the entire study is
categorized as non-therapeutic and was suspended due to this litigation. Only because federally-funded studies were exempted and this
study is part of the research program in a National Institute of Mental
Health-funded Child Center grant, could this study be resumed. If
the plaintiffs were successful in their attempt in the court of appeals to
halt such federally-funded studies as well, this research project would
have been prohibited. It is clear from plaintiffs' letter to the New York
Times,125 that they expected the T.D. litigation to impact all medical
research. Thus, for example, if a child developed leukemia and the
parents of the child wished to enroll their child in a treatment research protocol involving a promising new medication not yet otherwise available, the parents would be unable to do so if the study

120. See Peter Nordstrom et al., CSF 5-HIAA Predicts Suicide Risk After Attempted Suicide, 24
SUICIDE & LIFE-THREATENING BEHAVIOR 1, 2 (1994).

121. See Benedetto Vitiello & Peter S. Jensen, Medication Development and Testing in Children and Adolescents: CurrentProblems, FutureDirections, 54 ARCHIVES GEN. PSYCHIATRY, 871-76
(1997).
122. See Biological Studies in Suicidal Adolescent Inpatients, Fed. Grant No.3 Rol MH
47113-0451 (unpublished protocol on file with co-authorJohn Oldham, M.D.) This multisite treatment study sought to study the effects of some antidepressant medications on
children diagnosed with depression, suicidal tendencies, or anxiety. See id. at 113. The
NYPI inpatient research ward supplied "all supportive inpatient services, including psychological assessment, close nursing care, and careful medical supervision." Id.
123. See id. at 113. "Both parent and adolescent are provided with their own consent
forms, and both must sign before the study begins." Id. There are "two safeguards" established by this protocol: 1) both must sign the consent form, and 2) "the adolescent has at
least a week between the time of signing consent and the beginning of the biological tests
to change his or her mind." Id.
124. See ROBERT A. FISHMAN, CEREBROSPINAL FLUID DIsEASE OF THE NERVOUS SYSTEM 172

(2d ed. 1992).
125. Letter from Cliff Zucker et al., to Editor, N.Y. TIMES, January 7, 1997, at A16.
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included a non-therapeutic element such as a bone scan. Such a study
would be illegal in New York State.
Throughout the litigation, the defendants attempted to impress
upon plaintiffs the adverse impact on research that would occur if
they prevailed. At one point we presented them with a hypothetical
example" 6 in the hopes that they would at least recognize the problematic consequences of the rules they sought to establish, The hypothetical situation involved a medication X, a new anti-psychotic agent
that is thought to be very effective if treatment commenced immediately following acute onset of the illness. The research would include
individuals in their early twenties, thus unlikely to have executed advance directives, suffering from levels of disability that would likely
render them incapable of giving informed consent. The relative
safety of X has been established in FDA-regulated Phase I/I1 trials,
and an IRB is considering a Phase III pilot protocol to study the degree of efficacy. A brain scan or lumbar puncture is needed to understand X's locus of action in the brain and its metabolic impact on the
patient's health and on the disease processes, in order, ultimately, to
develop the next generation of safer, more effective medication. Such
procedures were necessary to complete the development of medication X and to obtain its FDA approval. The rules which plaintiffs seek
to establish would absolutely prohibit this research." 7
V.

CONCLUSION

Research must be done in a careful, thoughtful, and heavily reviewed and scrutinized way. It must be done ethically and respectfully, attending to patients' rights. These critical concerns, however,
must be integrated with the need to make available promising treatments for devastating illnesses as well as the need to continue the development of better treatments, which can only be discovered through
research. A plan like the Maryland proposal accomplishes such a desirable balance. Unfortunately, the results to date of the court process
in New York do not, in our opinion, achieve this goal.

126. Letter from Stephan Haimowitz to Cliff Zucker, attorney representative for plaintiffs, also working with public service law office serving persons with mental and physical
disabilities and Ruth Lowenkron (November 1, 1995) (copy on file with co-author Stephan
Haimowitz, J.D.).
127. When presented with this scenario, plaintiffs responded that the problem would
rarely arise because such studies could probably be done with patients who were capable or
had executed advance directives, but if not, the research should be banned, regardless of
the consequences. Telephone conversation between Stephan Haimowitz, Cliff Zucker and
Ruth Lowenkron (November 21, 1995).

